Focus Rheums| Dr. Jekyll or Mr. Hyde? (video)

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

1 Step Closer: Study Examines Factors That Lead to RA in Hope of Developing Prevention Strategies

  |  

Designed at Colorado University’s Anschutz Medical Campus, which is also the lead site for the study, along with 18 other institutions across the country.

“We’re continuing to enroll subjects in the study, and we expect to have answers within the next several years,” Dr. Deane says. “Those who have a family history of RA or elevated RA-related biomarkers are encouraged to enroll in our study.”

ADVERTISEMENT
SCROLL TO CONTINUE

To learn more about the RA study or how to enroll patients, visit Stop-RA.org.

Linda Childers is a health writer located in the San Francisco Bay Area.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Kelmenson LB, Wagner BD, McNair BK, et al. Timing of elevations of autoantibody isotypes in rheumatoid arthritis prior to disease diagnosis. Arthritis Rheumatol. 2019 Aug 29. doi: 10.1002/art.41091. [Epub ahead of print]
  2. National Institute of Allergy and Infectious Diseases. Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) [NCT02603146]. ClinicalTrials.gov. 2020 Apr 1.

Related Articles
    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Researchers Seek to Predict & Prevent Rheumatoid Arthritis

    Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…

    To Treat or Not to Treat? The Great Debate on Treatment of Subclinical Rheumatoid Arthritis

    PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing…

    2015 ACR/ARHP Annual Meeting: RA Pathogenesis and Prevention

    SAN FRANCISCO—Evolving research into the pathogenesis of rheumatoid arthritis (RA) is increasingly showing that rather than a single causative dysfunctional pathway leading to disease, multiple pathways are involved, the study of which can shed additional light on what is occurring in a person’s body prior to developing symptoms of disease. Saying it another way, no…